Halkid (Haloperidol)

Halkid (haloperidol) is indicated for the management of several psychiatric disorders where dopamine dysregulation is implicated.

• Schizophrenia, including acute exacerbations and maintenance therapy.
• Acute psychotic episodes associated with mood disorders or substance use.
• Manic episodes in bipolar disorder when rapid control of agitation is required.
• Severe agitation or hostility in patients with dementia, when non‑pharmacologic measures are insufficient (off‑label in some regions).
• Adjunctive treatment for Tourette syndrome or other hyperkinetic movement disorders (off‑label).

Haloperidol may cause a range of adverse effects that vary in frequency and severity, affecting multiple organ systems.

Common

• Drowsiness or sedation.
• Extrapyramidal symptoms such as tremor, rigidity, or akathisia.
• Dry mouth, constipation, or blurred vision.
• Weight gain or increased appetite.
• Orthostatic hypotension, leading to dizziness upon standing.
• Nausea or vomiting.

Serious

• Neuroleptic malignant syndrome, a life‑threatening reaction with fever and muscle rigidity.
• Tardive dyskinesia, characterized by involuntary, repetitive movements.
• Cardiac arrhythmias, including QT prolongation.
• Severe depression or suicidal thoughts.
• Hepatic dysfunction indicated by elevated liver enzymes.

When prescribing Halkid, clinicians should consider several precautionary measures to minimize risks and ensure safe use.

• Assess for a history of cardiovascular disease, as haloperidol can prolong the QT interval.
• Evaluate for prior movement disorders or extrapyramidal symptoms before initiating therapy.
• Use caution in patients with hepatic or renal impairment; dose adjustments may be necessary.
• Monitor for signs of neuroleptic malignant syndrome, especially during rapid dose escalation.
• Avoid use in individuals with known hypersensitivity to haloperidol or other butyrophenones.
• Consider pregnancy and lactation status; the drug’s safety profile in these populations is not well established.

Haloperidol can interact with other medications, potentially altering its efficacy or increasing adverse effects.

Avoid

• Other QT‑prolonging agents (e.g., certain antiarrhythmics, macrolide antibiotics) that may raise the risk of cardiac arrhythmias.
• CNS depressants such as benzodiazepines or opioids, which can enhance sedation and respiratory depression.
• Anticholinergic drugs that may mask extrapyramidal symptoms.

Use with caution

• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) which can increase haloperidol plasma levels.
• CYP3A4 inducers (e.g., carbamazepine, rifampin) that may reduce therapeutic concentrations.
• Lithium, as combined use may increase the risk of neurotoxicity.